MIRM250117P20000
- 0.00
- 0.000.00%
Mirum Pharmaceuticals Newsroom
Express News | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
JMP Securities Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $74
Mirum Pharmaceuticals Price Target Raised to $74 From $69 at JMP Securities
Would Mirum Pharmaceuticals (NASDAQ:MIRM) Be Better Off With Less Debt?
Mirum Shares Surge More Than 90% in 6 Months: Here's Why
Analysts Are Bullish on These Healthcare Stocks: Annexon Biosciences (ANNX), Mirum Pharmaceuticals (MIRM)
Express News | Mirum Pharmaceuticals Inc : JP Morgan Raises Target Price to $54 From $39
Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results
Evercore Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $68
Mirum Pharmaceuticals To Showcase Data From Its LIVMARLI And Volixibat Clinical Programs At AASLD's The Liver Meeting November 15-19, 2024
Mirum Pharmaceuticals Price Target Maintained With a $66.00/Share by HC Wainwright & Co.
Morgan Stanley Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $60
A Quick Look at Today's Ratings for Mirum Pharmaceuticals(MIRM.US), With a Forecast Between $50 to $70
Mirum Pharmaceuticals Is Maintained at Outperform by Baird
Mirum Pharmaceuticals Analyst Ratings
Mirum Pharmaceuticals' Strong Growth and Positive Outlook Driven by LIVMARLI Sales and Anticipated Chenodal Approval
Promising Outlook for Mirum Pharmaceuticals: Buy Rating Justified by Strong Performance and Strategic Initiatives
Express News | Mirum Pharmaceuticals Inc : Morgan Stanley Raises Target Price to $60 From $59
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript Summary
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript